|
Prospect Venture Partners is a dedicated life science venture capital firm with over $1 billion of capital under management. David has led private investments for and/or served on the board of directors of numerous public and private companies including Gloucester Pharmaceuticals, Healtheon, Microcide Pharmaceuticals, Neurocrine Biosciences, Rinat Neuroscience, Senomyx, Somaxon Pharmaceuticals, Trine, and Trubion Pharmaceuticals. David received an MD from Harvard Medical School, an MA in Health Services Research from Stanford University School of Medicine, and a BS in Biological Sciences from Stanford University. | 